SCM
BCAX

SCS Capital Management’s Bicara Therapeutics BCAX Stock Holding History

SCS Capital Management’s Portfolio BCAX Stock Details BCAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.06M Hold
53,430
– – 0.01% 269
2025
Q4 		$899K Hold
53,430
– – 0.01% 293
2025
Q3 		$844K Hold
53,430
– – 0.01% 305
2025
Q2 		$496K Buy
+53,430
New +$637K 0.01% 389

Other funds holding BCAX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RTM
Red Tree Management Redwood City, California $112M AUM 91.52% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

SCS Capital Management's BCAX Position: Q1 2026 in Review

SCS Capital Management held its Bicara Therapeutics (BCAX) position steady in Q1 2026 at 53,430 shares worth $1.06M. The position accounts for 0.01% of the portfolio, ranked #269.

SCS Capital Management first reported a position in BCAX in Q2 2025 and has held it in 4 quarters since. 146 funds tracked by Wall St. Rank hold BCAX as of Q1 2026.

  • SCS Capital Management held 53,430 shares of Bicara Therapeutics worth $1.06M as of Q1 2026.
  • SCS Capital Management left its Bicara Therapeutics share count unchanged in Q1 2026.
  • Bicara Therapeutics made up 0.01% of SCS Capital Management's portfolio in Q1 2026, its #269 holding.
  • SCS Capital Management first reported a position in Bicara Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • 146 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q1 2026.

Based on SCS Capital Management's 13F filing for Q1 2026, filed 11 May 2026.